Xconomy Boston

CombinatoRx Diabetes Drug Shows Promise

Ryan McBride5/27/09

CombinatoRx (NASDAQ:CRXX) reports that its Type 2 diabetes treatment, a combination of bezafibrate and diflunisal, provided statistically significant reduction in blood sugar levels and other benefits in a mid-stage clinical trial. It’s a bit of good news for Cambridge, MA-based CombinatoRx after it revealed last October that its lead arthritis drug failed in a Phase II trial.

Next Post

Related Topics

Related Posts

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Xconomy Events

Xconomy Forum: Mobile Madness 2012—Total Mobility

Register or Learn More

Xconomy’s Most Popular

  1. The 10 Social News Apps You Need to Try
  2. 7 Lessons from TechStars’ David Cohen on Building a Startup Culture
  3. Q4 Venture Deals, Dollars Stayed Strong, Making 2011 Best in a Decade
  4. With TV App, Dijit Hopes to Ride Out the Coming Apple Revolution in TV
  5. 10 Apps & Sites That Bring Back the Joy of Reading

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.